| Heather C Morgan, AAC | |
|
550 Peachtree St Ne, Atlanta, GA 30308-2212 | |
| (404) 558-0391 | |
| Not Available |
| Full Name | Heather C Morgan |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 11 Years |
| Location | 550 Peachtree St Ne, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346676947 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 6936 (Georgia) | Secondary |
| 367H00000X | Anesthesiologist Assistant | 006936 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emory University Hospital Midtown | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Emory Clinic, Inc | 8820901408 | 2687 |
News Archive
Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.
Researchers from the Structural Biology Computational Group of the Spanish National Cancer Research Centre, led by Alfonso Valencia, in collaboration with a group headed by Francesco Gervasio at the University College London (UK), have developed the first computational method based on evolutionary principles to predict protein dynamics, which explains the changes in the shape or dimensional structure that they experience in order to interact with other compounds or speed up chemical reactions.
The availability of sugar-sweetened or diet soda in schools does not appear to be related to students' overall consumption, except for African-American students, who drink more soda when it's available at school, finds a study in the American Journal of Preventive Medicine.
Millennium HealthCare Inc. today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location.
› Verified 7 days ago
| Entity Name | The Emory Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396798229 PECOS PAC ID: 8820901408 Enrollment ID: O20031110000503 |
News Archive
Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.
Researchers from the Structural Biology Computational Group of the Spanish National Cancer Research Centre, led by Alfonso Valencia, in collaboration with a group headed by Francesco Gervasio at the University College London (UK), have developed the first computational method based on evolutionary principles to predict protein dynamics, which explains the changes in the shape or dimensional structure that they experience in order to interact with other compounds or speed up chemical reactions.
The availability of sugar-sweetened or diet soda in schools does not appear to be related to students' overall consumption, except for African-American students, who drink more soda when it's available at school, finds a study in the American Journal of Preventive Medicine.
Millennium HealthCare Inc. today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location.
› Verified 7 days ago
| Entity Name | Emory Specialty Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407864168 PECOS PAC ID: 3476559782 Enrollment ID: O20061010000447 |
News Archive
Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.
Researchers from the Structural Biology Computational Group of the Spanish National Cancer Research Centre, led by Alfonso Valencia, in collaboration with a group headed by Francesco Gervasio at the University College London (UK), have developed the first computational method based on evolutionary principles to predict protein dynamics, which explains the changes in the shape or dimensional structure that they experience in order to interact with other compounds or speed up chemical reactions.
The availability of sugar-sweetened or diet soda in schools does not appear to be related to students' overall consumption, except for African-American students, who drink more soda when it's available at school, finds a study in the American Journal of Preventive Medicine.
Millennium HealthCare Inc. today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heather C Morgan, AAC Po Box 1076, Gainesville, GA 30503-1076 Ph: (770) 532-7179 | Heather C Morgan, AAC 550 Peachtree St Ne, Atlanta, GA 30308-2212 Ph: (404) 558-0391 |
News Archive
Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.
Researchers from the Structural Biology Computational Group of the Spanish National Cancer Research Centre, led by Alfonso Valencia, in collaboration with a group headed by Francesco Gervasio at the University College London (UK), have developed the first computational method based on evolutionary principles to predict protein dynamics, which explains the changes in the shape or dimensional structure that they experience in order to interact with other compounds or speed up chemical reactions.
The availability of sugar-sweetened or diet soda in schools does not appear to be related to students' overall consumption, except for African-American students, who drink more soda when it's available at school, finds a study in the American Journal of Preventive Medicine.
Millennium HealthCare Inc. today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location.
› Verified 7 days ago